BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

Benzinga · 1d ago
BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $89 price target.